BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Hong-Yu Yuan, Xiao-Lan Zhang, Xue-Hui Zhang, Ling Meng, Ji-Fu Wei. Analysis of patents on anti-rheumatoid arthritis therapies issued in ChinaExpert Opinion on Therapeutic Patents 2015; 25(8): 909 doi: 10.1517/13543776.2015.1044972
2
Licia Maria Henrique da Mota, Bóris Afonso Cruz, Cleandro Pires de Albuquerque, Deborah Pereira Gonçalves, Ieda Maria Magalhães Laurindo, Ivanio Alves Pereira, Jozélio Freire de Carvalho, Geraldo da Rocha Castelar Pinheiro, Manoel Barros Bertolo, Maria Raquel da Costa Pinto, Paulo Louzada‐Junior, Ricardo Machado Xavier, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima. Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoideRevista Brasileira de Reumatologia 2015; 55(6): 512 doi: 10.1016/j.rbr.2015.08.004
3
Séverine Vermeire, Stefan Schreiber, Robert Petryka, Tanja Kuehbacher, Xavier Hebuterne, Xavier Roblin, Maria Klopocka, Adrian Goldis, Maria Wisniewska-Jarosinska, Andrey Baranovsky, Robert Sike, Kremena Stoyanova, Chantal Tasset, Annegret Van der Aa, Pille Harrison. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialThe Lancet 2017; 389(10066): 266 doi: 10.1016/S0140-6736(16)32537-5
4
Huaxun Wu, Shangxue Yan, Jingyu Chen, Xuexia Luo, Peipei Li, Xiaoyi Jia, Xing Dai, Chun Wang, Qiong Huang, Lihua Liu, Yunfang Zhang, Aiwu Zhou, Yan Chang, LingLing Zhang, Wei Wei. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cellsJoint Bone Spine 2016; 83(5): 525 doi: 10.1016/j.jbspin.2015.09.002
5
Hideki Shimaoka, Shinsuke Takeno, Kenji Maki, Takahide Sasaki, Suguru Hasegawa, Yuichi Yamashita. A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancerOncology Letters 2017; 14(3): 3019 doi: 10.3892/ol.2017.6473
6
Selvaraj G. Nataraja, Henry N. Yu, Stephen S. Palmer. Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone ReceptorsFrontiers in Endocrinology 2015; 6 doi: 10.3389/fendo.2015.00142
7
Norma Elizabeth Vázquez-Herrera, Antonella Tosti. Current and future pharmacotherapy for alopecia areataExpert Opinion on Orphan Drugs 2015; 3(4): 419 doi: 10.1517/21678707.2015.1021778
8
Xiao Wu, Xuefang Zeng, Lei Wang, Taijun Hang, Min Song. Identification of related substances in tofacitinib citrate by LC-MS techniques for synthetic process optimizationJournal of Pharmaceutical and Biomedical Analysis 2017; 143: 17 doi: 10.1016/j.jpba.2017.05.012
9
Michael E. Weinblatt, Iain B. McInnes, Joel M. Kremer, Pedro Miranda, Jiri Vencovsky, Xiang Guo, Wendy I. White, Patricia C. Ryan, Alex Godwood, Marius Albulescu, David Close, Gerd R. Burmester. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid ArthritisArthritis & Rheumatology 2018; 70(1): 49 doi: 10.1002/art.40323
10
Feng Huang, Zu-chun Luo. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trialsClinical Rheumatology 2019; 38(2): 523 doi: 10.1007/s10067-018-4299-4
11
Young Ho Lee, Sang-Cheol Bae, Gwan Gyu Song. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trialsRheumatology International 2015; 35(12): 1965 doi: 10.1007/s00296-015-3291-4
12
Hart S. Dengler, Xiumin Wu, Ivan Peng, Cornelia H. Rinderknecht, Youngsu Kwon, Eric Suto, Pawan Bir Kohli, Marya Liimatta, Kathy Barrett, Julia Lloyd, Gary Cain, Mike Briggs, Stephanie Addo, Gary Salmon, Savita Ubhayakar, Gauri Deshmukh, Sheerin K. Shahidi-Latham, Cristine M. Quiason-Huynh, Janet Jackman, John Liu, Nicholas C. Ray, Simon C. Goodacre, Adam Johnson, Brent S. McKenzie, Wyne P. Lee, Mark Zak, Jane R. Kenny, Nico Ghilardi. Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthmaScience Translational Medicine 2018; 10(468): eaao2151 doi: 10.1126/scitranslmed.aao2151
13
Shivaprasad Venkatesha, Steven Dudics, Bodhraj Acharya, Kamal Moudgil. Cytokine-Modulating Strategies and Newer Cytokine Targets for Arthritis TherapyInternational Journal of Molecular Sciences 2014; 16(1): 887 doi: 10.3390/ijms16010887
14
Christina M. Rollings, Linda V. Sinclair, Hugh J. M. Brady, Doreen A. Cantrell, Sarah H. Ross. Interleukin-2 shapes the cytotoxic T cell proteome and immune environment–sensing programsScience Signaling 2018; 11(526): eaap8112 doi: 10.1126/scisignal.aap8112
15
Selvaraj Nataraja, Venkataraman Sriraman, Stephen Palmer. Allosteric Regulation of the Follicle-Stimulating Hormone ReceptorEndocrinology 2018; 159(7): 2704 doi: 10.1210/en.2018-00317
16
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park. Novel treatments for inflammatory bowel diseaseThe Korean Journal of Internal Medicine 2018; 33(1): 20 doi: 10.3904/kjim.2017.393
17
Patrick P.C. Boor, Petra E. de Ruiter, Patrick S. Asmawidjaja, Erik Lubberts, Luc J.W. van der Laan, Jaap Kwekkeboom. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfaTranslational Research 2017; 188: 67 doi: 10.1016/j.trsl.2016.11.006
18
Der-Yuan Chen, Ping-Ning Hsu, Chao-Hsiun Tang, Lindsay Claxton, Satish Valluri, Robert A. Gerber. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in TaiwanJournal of Medical Economics 2019; 22(8): 777 doi: 10.1080/13696998.2019.1606813
19
Mark Löwenberg, Geert D’Haens. Next-Generation Therapeutics for IBDCurrent Gastroenterology Reports 2015; 17(6) doi: 10.1007/s11894-015-0444-2
20
Hind M. Almohanna, Marina Perper, Antonella Tosti. Safety concerns when using novel medications to treat alopeciaExpert Opinion on Drug Safety 2018; 17(11): 1115 doi: 10.1080/14740338.2018.1533549
21
Licia Maria Henrique da Mota, Bóris Afonso Cruz, Cleandro Pires de Albuquerque, Deborah Pereira Gonçalves, Ieda Maria Magalhães Laurindo, Ivanio Alves Pereira, Jozélio Freire de Carvalho, Geraldo da Rocha Castelar Pinheiro, Manoel Barros Bertolo, Maria Raquel da Costa Pinto, Paulo Louzada-Junior, Ricardo Machado Xavier, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima. Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinibRevista Brasileira de Reumatologia (English Edition) 2015; 55(6): 512 doi: 10.1016/j.rbre.2015.09.003
22
Bálint Botz, Kata Bölcskei, Zsuzsanna Helyes. Challenges to develop novel anti-inflammatory and analgesic drugsWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2017; 9(3): e1427 doi: 10.1002/wnan.1427
23
Hiroaki Hayashi, Ryusuke Kaneko, Shunsuke Demizu, Daichi Akasaka, Manabu Tayama, Takafumi Harada, Hiroki Irie, Yoshio Ogino, Naoko Fujino, Eiji Sasaki. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent ModelsJournal of Pharmacology and Experimental Therapeutics 2018; 366(1): 84 doi: 10.1124/jpet.118.248153